Award from Bechtel includes supply of the primary liquefaction equipment for NextDecade’s Rio Grande LNG Train 5Order includes Frame 7 gas turbines and centrifugal compressors, replicating proven solutions from previous trainsTechnology will enable an additional LNG production capacity of approximately 6 MTPA HOUSTON and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Thursday an award from engineering company Bechtel Energy Inc. (Bechtel) to sup ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

Independent artists often pour countless hours — and pieces of themselves — into their work. Crystal Cox, owner of Spookshow Babe Design in New Berlin, Wisconsin, is one of them. Her studio is where she sketches, refines and builds the designs that support her business. Must Read In 2023, Cox posted a print she called Spooky Scoops to her Instagram. But two years later, she started receiving messages from friends and customers who said they’d spotted three-dimensional versions of her design for sale at ...

Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral presentation at ASH 2025 Company to share initial data for CLN-978, a CD19xCD3 bispecific T cell engager, in both SLE and RA in first half of 2026 Based on review of emerging clinical data, CLN-619 and CLN-617 programs discontinued Cash and investments of $475.5 million as of September 30, 2 ...

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5First participant enrolled in run-in period for planned adaptive Phase 3 trialCompany intends to apply for the FDA’s new Rare Disease Evidence Principles (RDEP) review processOPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for Leber congenital amaurosis (LCA) type 5Recent $23 million financing led by Perceptive Advisors and Baly ...

- Record Quarterly Revenue of $260.5 Million, Up 9.3% Year-Over-Year Led by 7.6% Organic Growth - - Single-Family Residential Business and Multi-Family/Commercial Business Each Achieved Record Quarterly Revenues Through Market Share Gains and Geographic Expansion - - Net Income of $47.2 Million, or $1.01 Per Diluted Share, Marking the Second Most Profitable Quarter in the History of the Company - - Adjusted Net Income1 of $46.7 Million, or $1.00 Per Diluted Share - - Adjusted EBITDA1 of $79.1 Million, Repre ...

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public offering Ended the quarter with $513.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology’s (ASN) Kidney Week, being held November 6-9 in Houston, Texas. During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, as wel ...

- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it has en ...